BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24005342)

  • 21. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation.
    Murata A; Okamoto K; Mayumi T; Muramatsu K; Matsuda S
    Int J Clin Pharm; 2015 Feb; 37(1):139-47. PubMed ID: 25515615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Combined Thrombomodulin and Antithrombin in Anticoagulant Therapy for Acute Cholangitis-induced Disseminated Intravascular Coagulation.
    Morita N; Nakahara K; Morita R; Suetani K; Michikawa Y; Sato J; Tsuji K; Ikeda H; Matsunaga K; Watanabe T; Matsumoto N; Okuse C; Suzuki M; Itoh F
    Intern Med; 2019 Apr; 58(7):907-914. PubMed ID: 30449812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis.
    Okuda A; Ogura T; Imanishi M; Miyano A; Nishioka N; Higuchi K
    Gut Liver; 2018 Jul; 12(4):471-477. PubMed ID: 29699063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
    Ouchi K; Takahashi S; Chikamatsu S; Ito S; Takahashi Y; Kawai S; Okita A; Kasahara Y; Okada Y; Imai H; Komine K; Saijo K; Takahashi M; Shirota H; Takahashi M; Gamoh M; Ishioka C
    Int J Clin Oncol; 2018 Aug; 23(4):790-798. PubMed ID: 29511940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum thrombomodulin as a prognostic marker of disseminated intravascular coagulation.
    Kotajima N; Kanda T; Fukumura Y; Kobayashi I
    J Med; 1999; 30(1-2):19-29. PubMed ID: 10515237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation.
    Kimpara N; Tawara S; Kawasaki K
    Thromb Res; 2019 Jul; 179():73-80. PubMed ID: 31096113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Thrombomodulin Alfa on Disseminated Intravascular Coagulation in Patients with Lung Cancer.
    Nakano K; Sugiyama K; Satoh H; Arifuku H; Fujimatsu T; Yoshida N; Watanabe H; Tokita S; Wakayama T; Tatewaki M; Souma R; Masuda H; Koyama K; Hirata H; Fukushima Y
    Intern Med; 2017; 56(14):1799-1806. PubMed ID: 28717074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant human soluble thrombomodulin treatment for disseminated intravascular coagulation at a single institution--an analysis of 62 cases caused by infectious diseases and 30 cases caused by hematological diseases.
    Kawano N; Tasaki A; Kuriyama T; Tahara Y; Yoshida S; Ono N; Himeji D; Yamashita K; Shibata Y; Goto T; Inoue T; Yokota-Ikeda N; Uezono S; Yuge A; Nishiguchi T; Kinjo T; Ogura Y; Beppu K; Ueda Y; Kinoshita M; Moritake H; Shimoda K; Ochiai H; Ueda A
    Intern Med; 2014; 53(3):205-13. PubMed ID: 24492688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan: An Epidemiological Study Based on a National Administrative Database.
    Murata A; Okamoto K; Mayumi T; Muramatsu K; Matsuda S
    Clin Appl Thromb Hemost; 2016 Jan; 22(1):21-7. PubMed ID: 25736054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution.
    Kawano N; Yoshida S; Ono N; Himeji D; Nagahiro Y; Sayaka Kawano ; Yamashita K; Ikeda N; Uezono S; Ochiai H; Kawano F; Kikuchi I; Ishikawa F; Shimoda K; Ueda A; Akashi K
    J Clin Exp Hematop; 2011; 51(2):101-7. PubMed ID: 22104308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.
    Imaura M; Tsumori M; Nagase S; Omura K; Takahashi H; Hatoyama-Tanaka S; Katagiri F; Takayanagi R; Kanno H; Yamada Y
    Shock; 2020 Jul; 54(1):50-55. PubMed ID: 31764622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment responses for disseminated intravascular coagulation in 25 children treated with recombinant thrombomodulin: a single institution experience.
    Yagasaki H; Kato M; Shimozawa K; Hirai M; Nishikawa E; Okuma H; Ishii W; Imai Y; Matsumura M; Yonezawa R; Yoshikawa K; Shichino H; Chin M; Mugishima H
    Thromb Res; 2012 Dec; 130(6):e289-93. PubMed ID: 23123162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats.
    Gonda Y; Hirata S; Saitoh K; Aoki Y; Mohri M; Gomi K; Sugihara T; Kiyota T; Yamamoto S; Ishida T
    Thromb Res; 1993 Aug; 71(4):325-35. PubMed ID: 8236161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early thrombomodulin-α administration outcome for acute disseminated intravascular coagulopathy in gastrointestinal surgery.
    Konishi H; Okamoto K; Shoda K; Arita T; Kosuga T; Morimura R; Komatsu S; Murayama Y; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Otsuji E
    World J Gastroenterol; 2017 Feb; 23(5):891-898. PubMed ID: 28223734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant Human Soluble Thrombomodulin Contributes to a Reduction In-Hospital Mortality of Acute Cholangitis with Disseminated Intravascular Coagulation: A Propensity Score Analyses of a Japanese Nationwide Database.
    Tarasawa K; Fujimori K; Fushimi K
    Tohoku J Exp Med; 2020 Sep; 252(1):53-61. PubMed ID: 32879147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.